EQS — News: Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026

EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026 24.09.2026 / 10:33 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ Press Release Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026 • Recommended Phase 2 Dose (RP2D) of 175 µg/kg for pamlectabart tismanitin established based on Phase I data • Favorable safety profile observed across dose escalation, with the maximum tolerated dose (MTD) not reached • Phase IIa dose expansion in patients with relapsed or refractory multiple myeloma (RRMM) progressing according to plan Ladenburg, Germany, 24 September 2026 — Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), presented new data from its Phase I/IIa clinical study with its lead Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101), at the 23^rd International Myeloma Society (IMS) Annual Meeting in Glasgow